Finn Myhren
- Physiology top 10%
-
- Drug Transport and Resistance Mechanisms 3
-
- HIV/AIDS drug development and treatment 6
-
- Cytomegalovirus and herpesvirus research 4
- Herpesvirus Infections and Treatments 3
-
- Chronic Lymphocytic Leukemia Research 3
-
- Biochemical and Molecular Research 3
- Cancer therapeutics and mechanisms 2
-
- Bioactive Compounds and Antitumor Agents 1
- Co-authors
- Marit Liland SandvoldGodefridus J. PetersHans R. HendriksAndries M. BergmanØystein FodstadJan BalzariniErik De ClercqC.M. Kuiper
- Cited by
- PhysiologyHematologyBiomaterials
- Journals
- Antimicrobial Agents and Chemotherapy (1 paper)Biochemical Pharmacology (1 paper)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- NetherlandsNorwayBelgium
In The Last Decade
Finn Myhren
17 papers receiving 419 citations
Peers
Comparison fields: 5 of 65
- Physiology 35
- Hematology 55
- Biomaterials 64
- Oncology 124
- Infectious Diseases 79
Countries citing papers authored by Finn Myhren
This map shows the geographic impact of Finn Myhren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Finn Myhren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Finn Myhren more than expected).
Fields of papers citing papers by Finn Myhren
This network shows the impact of papers produced by Finn Myhren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Finn Myhren. The network helps show where Finn Myhren may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Finn Myhren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 42 | |
| 2 | 2010 | 78 | |
| 3 | 2010 | 15 | |
| 4 | 2010 | 12 | |
| 5 | 2008 | 26 | |
| 6 | Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab, and trastuzumab in human NSCLC xenografts | 2007 | 2 |
| 7 | 2004 | 22 | |
| 8 | 2004 | 25 | |
| 9 | 2003 | 73 | |
| 10 | 2000 | 14 | |
| 11 | 1999 | 8 | |
| 12 | 1999 | 4 | |
| 13 | Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. | 1999 | 63 |
| 14 | 1998 | 23 | |
| 15 | 1997 | 20 | |
| 16 | 1986 | 8 | |
| 17 | 1986 | 3 |
About Finn Myhren
Finn Myhren is a scholar working on Infectious Diseases, Oncology and Toxicology, having authored 17 papers that have together received 438 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (6 papers), Cytomegalovirus and herpesvirus research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), Drug Transport and Resistance Mechanisms (3 papers), Biochemical and Molecular Research (3 papers), Herpesvirus Infections and Treatments (3 papers), Cancer therapeutics and mechanisms (2 papers) and Bioactive Compounds and Antitumor Agents (1 paper). The work is most often cited by research in Physiology (35 citations), Hematology (55 citations) and Biomaterials (64 citations). Finn Myhren has collaborated with scholars based in Netherlands, Norway and Belgium. Frequent co-authors include Marit Liland Sandvold, Godefridus J. Peters, Hans R. Hendriks, Andries M. Bergman, Øystein Fodstad, Jan Balzarini, Erik De Clercq, C.M. Kuiper, Daphne Voorn and Knut Breistøl. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Biochemical Pharmacology and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.